Tracks: Late-Breaking Trials Session Four
Gregg Stone, MD, FACC, MSCAI (he/him/his)
Physician
Mount Sinai
New York, New York, United States
Disclosure(s): Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo and V-wave: University Grants/Research Support (Ongoing); Abiomed, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Amgen, Millennia Biopharma: Consultant (Terminated); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Medtronic, Pulnovo, Infraredx: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical: Consultant (Ongoing)